Logo image of ISRG

INTUITIVE SURGICAL INC (ISRG) Stock Fundamental Analysis

NASDAQ:ISRG - Nasdaq - US46120E6023 - Common Stock - Currency: USD

480.02  +2.94 (+0.62%)

Fundamental Rating

7

Taking everything into account, ISRG scores 7 out of 10 in our fundamental rating. ISRG was compared to 187 industry peers in the Health Care Equipment & Supplies industry. ISRG has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. ISRG is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ISRG suitable for growth and quality investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

ISRG had positive earnings in the past year.
ISRG had a positive operating cash flow in the past year.
In the past 5 years ISRG has always been profitable.
ISRG had a positive operating cash flow in each of the past 5 years.
ISRG Yearly Net Income VS EBIT VS OCF VS FCFISRG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

1.2 Ratios

ISRG has a Return On Assets of 12.93%. This is amongst the best in the industry. ISRG outperforms 94.65% of its industry peers.
ISRG has a Return On Equity of 14.52%. This is amongst the best in the industry. ISRG outperforms 90.37% of its industry peers.
The Return On Invested Capital of ISRG (13.28%) is better than 94.65% of its industry peers.
ISRG had an Average Return On Invested Capital over the past 3 years of 12.20%. This is above the industry average of 8.03%.
The last Return On Invested Capital (13.28%) for ISRG is above the 3 year average (12.20%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROIC 13.28%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ISRG Yearly ROA, ROE, ROICISRG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

ISRG's Profit Margin of 28.51% is amongst the best of the industry. ISRG outperforms 95.72% of its industry peers.
ISRG's Profit Margin has declined in the last couple of years.
ISRG has a better Operating Margin (28.93%) than 97.33% of its industry peers.
In the last couple of years the Operating Margin of ISRG has declined.
ISRG's Gross Margin of 66.61% is fine compared to the rest of the industry. ISRG outperforms 71.12% of its industry peers.
ISRG's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
ISRG Yearly Profit, Operating, Gross MarginsISRG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

7

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so ISRG is still creating some value.
ISRG has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ISRG has been increased compared to 5 years ago.
There is no outstanding debt for ISRG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ISRG Yearly Shares OutstandingISRG Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ISRG Yearly Total Debt VS Total AssetsISRG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

ISRG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.5
WACC8.88%
ISRG Yearly LT Debt VS Equity VS FCFISRG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.3 Liquidity

A Current Ratio of 5.64 indicates that ISRG has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.64, ISRG belongs to the top of the industry, outperforming 80.21% of the companies in the same industry.
A Quick Ratio of 4.89 indicates that ISRG has no problem at all paying its short term obligations.
ISRG has a Quick ratio of 4.89. This is amongst the best in the industry. ISRG outperforms 80.21% of its industry peers.
Industry RankSector Rank
Current Ratio 5.64
Quick Ratio 4.89
ISRG Yearly Current Assets VS Current LiabilitesISRG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

8

3. Growth

3.1 Past

ISRG shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 26.97%, which is quite impressive.
ISRG shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 11.48% yearly.
The Revenue has grown by 20.77% in the past year. This is a very strong growth!
The Revenue has been growing by 13.27% on average over the past years. This is quite good.
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%

3.2 Future

ISRG is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.45% yearly.
The Revenue is expected to grow by 14.12% on average over the next years. This is quite good.
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue Next Year19.56%
Revenue Next 2Y16.91%
Revenue Next 3Y16.15%
Revenue Next 5Y14.12%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
ISRG Yearly Revenue VS EstimatesISRG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B
ISRG Yearly EPS VS EstimatesISRG Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5 10 15

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 59.63, the valuation of ISRG can be described as expensive.
Based on the Price/Earnings ratio, ISRG is valued a bit cheaper than the industry average as 67.91% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.93, ISRG is valued quite expensively.
ISRG is valuated quite expensively with a Price/Forward Earnings ratio of 52.04.
Based on the Price/Forward Earnings ratio, ISRG is valued a bit cheaper than 66.84% of the companies in the same industry.
ISRG is valuated rather expensively when we compare the Price/Forward Earnings ratio to 35.31, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 59.63
Fwd PE 52.04
ISRG Price Earnings VS Forward Price EarningsISRG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ISRG is valued a bit cheaper than the industry average as 64.71% of the companies are valued more expensively.
ISRG's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. ISRG is cheaper than 70.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 86.28
EV/EBITDA 50.14
ISRG Per share dataISRG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of ISRG may justify a higher PE ratio.
ISRG's earnings are expected to grow with 13.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)6.55
PEG (5Y)5.19
EPS Next 2Y12.18%
EPS Next 3Y13.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ISRG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTUITIVE SURGICAL INC

NASDAQ:ISRG (8/15/2025, 10:05:08 AM)

480.02

+2.94 (+0.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)07-22 2025-07-22/amc
Earnings (Next)10-15 2025-10-15/amc
Inst Owners88.73%
Inst Owner Change-0.93%
Ins Owners0.45%
Ins Owner Change6.2%
Market Cap172.08B
Analysts79
Price Target598.96 (24.78%)
Short Float %1.09%
Short Ratio2.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.33%
Min EPS beat(2)3.05%
Max EPS beat(2)11.61%
EPS beat(4)4
Avg EPS beat(4)11.45%
Min EPS beat(4)3.05%
Max EPS beat(4)20.76%
EPS beat(8)8
Avg EPS beat(8)8.83%
EPS beat(12)11
Avg EPS beat(12)6.4%
EPS beat(16)13
Avg EPS beat(16)4.58%
Revenue beat(2)2
Avg Revenue beat(2)1.47%
Min Revenue beat(2)1.09%
Max Revenue beat(2)1.84%
Revenue beat(4)3
Avg Revenue beat(4)1.98%
Min Revenue beat(4)-0.14%
Max Revenue beat(4)5.12%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)6
Avg Revenue beat(12)0.42%
Revenue beat(16)7
Avg Revenue beat(16)0.13%
PT rev (1m)0.9%
PT rev (3m)0.88%
EPS NQ rev (1m)2.08%
EPS NQ rev (3m)-2.78%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.65%
Revenue NQ rev (1m)0.78%
Revenue NQ rev (3m)0.66%
Revenue NY rev (1m)1.29%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE 59.63
Fwd PE 52.04
P/S 18.82
P/FCF 86.28
P/OCF 60.89
P/B 9.58
P/tB 9.77
EV/EBITDA 50.14
EPS(TTM)8.05
EY1.68%
EPS(NY)9.22
Fwd EY1.92%
FCF(TTM)5.56
FCFY1.16%
OCF(TTM)7.88
OCFY1.64%
SpS25.51
BVpS50.08
TBVpS49.11
PEG (NY)6.55
PEG (5Y)5.19
Profitability
Industry RankSector Rank
ROA 12.93%
ROE 14.52%
ROCE 14.74%
ROIC 13.28%
ROICexc 28.31%
ROICexgc 29.53%
OM 28.93%
PM (TTM) 28.51%
GM 66.61%
FCFM 21.81%
ROA(3y)11.41%
ROA(5y)11.26%
ROE(3y)13.21%
ROE(5y)12.97%
ROIC(3y)12.2%
ROIC(5y)11.86%
ROICexc(3y)18.44%
ROICexc(5y)19.03%
ROICexgc(3y)19.29%
ROICexgc(5y)20.12%
ROCE(3y)13.54%
ROCE(5y)13.16%
ROICexcg growth 3Y-7.59%
ROICexcg growth 5Y-7%
ROICexc growth 3Y-6.87%
ROICexc growth 5Y-6.06%
OM growth 3Y-4.19%
OM growth 5Y-1.68%
PM growth 3Y-2.34%
PM growth 5Y-2.02%
GM growth 3Y-0.91%
GM growth 5Y-0.58%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 144.66%
Cap/Sales 9.1%
Interest Coverage 250
Cash Conversion 87.74%
Profit Quality 76.48%
Current Ratio 5.64
Quick Ratio 4.89
Altman-Z N/A
F-Score6
WACC8.88%
ROIC/WACC1.5
Cap/Depr(3y)197.35%
Cap/Depr(5y)162.98%
Cap/Sales(3y)12.27%
Cap/Sales(5y)10.16%
Profit Quality(3y)56.77%
Profit Quality(5y)75.99%
High Growth Momentum
Growth
EPS 1Y (TTM)26.97%
EPS 3Y13.83%
EPS 5Y11.48%
EPS Q2Q%23.03%
EPS Next Y9.11%
EPS Next 2Y12.18%
EPS Next 3Y13.89%
EPS Next 5Y14.45%
Revenue 1Y (TTM)20.77%
Revenue growth 3Y13.51%
Revenue growth 5Y13.27%
Sales Q2Q%21.4%
Revenue Next Year19.56%
Revenue Next 2Y16.91%
Revenue Next 3Y16.15%
Revenue Next 5Y14.12%
EBIT growth 1Y34.69%
EBIT growth 3Y8.76%
EBIT growth 5Y11.37%
EBIT Next Year40.01%
EBIT Next 3Y23.31%
EBIT Next 5Y19.86%
FCF growth 1Y69.15%
FCF growth 3Y-9.1%
FCF growth 5Y2.14%
OCF growth 1Y52.09%
OCF growth 3Y4.95%
OCF growth 5Y8.61%